Product How it works Pricing Blog FAQ About Contact
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals (NASDAQ: REGN) free cash flow

Regeneron Pharmaceuticals reported free cash flow of $4,081m for fiscal 2025: $4,979m of operating cash flow minus $898.4m of capital expenditure. That is 11.3% more than in fiscal 2024. It equals 28.4% of revenue.

Free cash flow, in millions of US dollars974.020161,03520171,81220182,00020192,00420206,52920214,42520223,87520233,66520244,0812025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Free cash flow by fiscal year

Fiscal yearFree cash flowChangeOperating cash flowCapital expenditureShare of revenue
2025$4,081m+11.3%$4,979m$898.4m28.4%
2024$3,665m−5.4%$4,421m$755.9m25.8%
2023$3,875m−12.4%$4,594m$718.6m29.5%
2022$4,425m−32.2%$5,015m$590.1m36.3%
2021$6,529m+225.9%$7,081m$551.9m40.6%
2020$2,004m+0.2%$2,618m$614.6m23.6%
2019$2,000m+10.4%$2,430m$429.6m30.5%
2018$1,812m+75.2%$2,195m$383.1m35.2%
2017$1,035m+6.2%$1,307m$272.6m17.6%
2016$974.0m—$1,486m$511.9m20.0%

Free cash flow is operating cash flow minus capital expenditure, both from the cash flow statement in the same filing. The change compares each fiscal year with the one before and is not calculated when the previous year was negative. Figures are in millions of US dollars, except per-share amounts.

Questions about the free cash flow of Regeneron Pharmaceuticals

How much free cash flow did Regeneron Pharmaceuticals generate in fiscal 2025?
Regeneron Pharmaceuticals reported free cash flow of $4,081m for fiscal 2025. In fiscal 2024 it was free cash flow of $3,665m.
How is the free cash flow of Regeneron Pharmaceuticals calculated?
It is operating cash flow minus capital expenditure, both from the cash flow statement in its accounts: in fiscal 2025, $4,979m minus $898.4m.
What share of its revenue does Regeneron Pharmaceuticals turn into free cash flow?
In fiscal 2025, 28.4% of its revenue.
What was the best year for free cash flow at Regeneron Pharmaceuticals?
Of its last 10 fiscal years, fiscal 2021, with $6,529m.
Where do the figures for Regeneron Pharmaceuticals come from?
From the annual report (Form 10-K) that Regeneron Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Regeneron Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Regeneron Pharmaceuticals: the Regeneron Pharmaceuticals page · annual accounts · revenue · net income · dividends paid · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.